Mengkritisi Iklan Layanan Masyarakat (ILM) Kita

Public service advertising is becoming one way to reach communication purpose in Indonesia from both public and private institutions. However, more public service advertisings are having problems in its internal surrounding. For instance, dishonesty factor to be presented, only lips service or to cover weakness of an organization or corporation. The critical review will aim to one balance understanding about how public service advertising presents well from who delivered the message, to what purpose the advertising is delivered and how, and to which community groups the advertising is aiming. Finally, the public service advertising will be the effective way because it has variables that supposed to be had by public service advertising

MICHE Competitions: A Realistic Experience with Uncontrolled Eye Region Acquisition

People struggle every day with authentication to access a protected service or location, or simply aimed at protecting one’s own devices. This spurs a growing demand for self-handled authentication strategies. The increasing number of remote services of various kinds corresponds to an increasing number of passwords to use and remember, and also to the growth of the password theft risk, due to the increasing value of the protected resources. The other core element in present authentication scenarios is the ubiquity of mobile equipment. Smartphones add a “whatever” dimension to the possible uses of the mobile devices whenever and wherever that include storing/transferring multimedia information, often personal and often sensitive. Biometrics can both enforce and simplify authentication in controlled environments. Mobile biometrics in uncontrolled settings, where there is no operator to guide the capture of a “good-quality” sample on a mobile device, is the new frontier for secure use of data and services. The iris is among the best candidates for biometric recognition. It is extremely discriminative: Right and left irises of the same person are so different to hinder a correct matching, because randotypic elements largely overcome genotypic ones in individual development. However, self-acquired samples often suffer from poor quality, due, e.g., to reflections, motion blurring, out of focus, or bad image framing. Mobile setting and especially the inherent problems related to uncontrolled iris image acquisition are addressed in the two challenges of the MICHE project, whose results are the core topic of this chapter

Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial

Background: The CRASH-3 trial hypothesised that timely tranexamic acid (TXA) treatment might reduce deaths from intracranial bleeding after traumatic brain injury (TBI). To explore the mechanism of action of TXA in TBI, we examined the timing of its effect on death. Methods: The CRASH-3 trial randomised 9202 patients within 3 h of injury with a GCS score ≤ 12 or intracranial bleeding on CT scan and no significant extracranial bleeding to receive TXA or placebo. We conducted an exploratory analysis of the effects of TXA on all-cause mortality within 24 h of injury and within 28 days, excluding patients with a GCS score of 3 or bilateral unreactive pupils, stratified by severity and country income. We pool data from the CRASH-2 and CRASH-3 trials in a one-step fixed effects individual patient data meta-analysis. Results: There were 7637 patients for analysis after excluding patients with a GCS score of 3 or bilateral unreactive pupils. Of 1112 deaths, 23.3% were within 24 h of injury (early deaths). The risk of early death was reduced with TXA (112 (2.9%) TXA group vs 147 (3.9%) placebo group; risk ratio [RR] RR 0.74, 95% CI 0.58–0.94). There was no evidence of heterogeneity by severity (p = 0.64) or country income (p = 0.68). The risk of death beyond 24 h of injury was similar in the TXA and placebo groups (432 (11.5%) TXA group vs 421 (11.7%) placebo group; RR 0.98, 95% CI 0.69–1.12). The risk of death at 28 days was 14.0% in the TXA group versus 15.1% in the placebo group (544 vs 568 events; RR 0.93, 95% CI 0.83–1.03). When the CRASH-2 and CRASH-3 trial data were pooled, TXA reduced early death (RR 0.78, 95% CI 0.70–0.87) and death within 28 days (RR 0.88, 95% CI 0.82–0.94). Conclusions: Tranexamic acid reduces early deaths in non-moribund TBI patients regardless of TBI severity or country income. The effect of tranexamic acid in patients with isolated TBI is similar to that in polytrauma. Treatment is safe and even severely injured patients appear to benefit when treated soon after injury. Trial registration: ISRCTN15088122, registered on 19 July 2011; NCT01402882, registered on 26 July 2011